/

Empresas

Me

No verificado

Merck & Co., Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

203 Comunicados de prensa

Ver todos los comunicados de prensa

30/04/2026

Web y redes sociales

Telefonía

Mercado de valores

Salud

Higiene alimentaria

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Fuente

Merck & Co., Inc.

Editor

1.00

0

28/04/2026

Mercado laboral

Industria

Béisbol

Salud

Deportes

Farmacéutica

Cardiología

Biotecnología

Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

Fuente

Merck & Co., Inc.

Editor

1.00

0

24/04/2026

Mercado de valores

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

Fuente

Merck & Co., Inc.

Editor

1.00

0

21/04/2026

FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)

Fuente

Merck & Co., Inc.

Editor

1.00

0

21/04/2026

Multimedia

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Fuente

Merck & Co., Inc.

Editor

1.00

0

17/04/2026

Industria

Higiene alimentaria

Salud

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

Farmacéutica

Biotecnología

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

Fuente

Merck & Co., Inc.

Editor

1.00

0

13/04/2026

Mercado laboral

Industria

Oncología

Salud

Sanidad

Medicina - Varios

Cardiología

Biotecnología

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Fuente

Merck & Co., Inc.

Editor

1.00

0

07/04/2026

Mercado laboral

Mercado de valores

Industria

Biotecnología

Salud

Ciencia

Farmacéutica

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Fuente

Merck & Co., Inc.

Editor

1.00

0

02/04/2026

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Óptica

Biotecnología

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

Fuente

Merck & Co., Inc.

Editor

1.00

0

02/04/2026

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

Fuente

Merck & Co., Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0